CF Foundation | Examining the Impact of Antimicrobial Resistance on Rare Disease Patients

Michael Boyle, the president and CEO of the Cystic Fibrosis Foundation, sits down with Amanda Jezek, the senior vice president of public policy and government relations at the Infectious Diseases Society of America (IDSA), at the World Orphan Drug Congress to discuss the issue of antimicrobial resistance, its impact on people living with rare diseases like cystic fibrosis, and policy solutions to this public health crisis. #WODCUSA

Originally recorded August 18, 2021.

0:00 | Examining the Impact of Antimicrobial Resistance on Rare Disease Patients
0:53 | How does antimicrobial resistance (AMR) relate to the rare disease community?
2:36 | What you should know about antimicrobial resistance
4:29 | Why is antimicrobial resistance is an important issue for people with cystic fibrosis?
8:22 | An overview on IDSA’s work AMR
10:30 | Dr. Boyle discusses different ways to address a waning pipeline
12:33 | What challenges do companies face when developing new antibiotics?
14:14 | What are potential solutions to strengthen the antibiotic pipeline?
16:20 | Dr. Boyle reflects on policy solutions, including the PASTEUR Act, that could help address some of these marketplace issues.
18:40 | What is IDSA is doing to support the reintroduction of the PASTEUR Act?
20:26 | What do you expect from the future of AMR?

[MrJ]

Will the use of trikafta assist in clearing previously chronic infections? Or is there any consensus on that theory at this stage?